Christian Hein · 20 November 2024 · 1 min read
This could be big: "Oura valued at $5B following deal with medical device firm Dexcom.
Oura's $5B valuation following its deal with Dexcom signals a powerful convergence of continuous glucose monitoring and consumer wearables — and I think it could be a game-changer for health optimization well beyond diabetic patients.
This could be big: "Oura valued at $5B following deal with medical device firm Dexcom."
Wow. The convergence of two major trends - continuous glucose monitoring (CGM), which is gaining traction even beyond diabetic patients, and the rise of consumer-friendly wearables - is truly intriguing.
This could be a game-changer - not just for managing chronic conditions but for overall health optimization; I could definitely see myself adopting this.
What do you think? Are we on the brink of a new wave of wearable health tech that could finally make potentially clinical-grade insights mainstream?
Connected Devices · Digital Health · Medtech · Digital Health Startups · Innovation Management · Partnership / Alliance
Related insights
24 Apr 2025
Biolinq raises $100M to disrupt glucose monitoring - but what makes their patch different?
5 Mar 2026
FDA GenAI clinical care regulation: why Breakthrough Device Designation matters
12 Jun 2025
One of the biggest paradoxes in health data: the most valuable insights are locked within the mo...
18 Mar 2025
AI in healthcare shouldn't aim to replace professionals - instead, its true potential lies in en...